US 11,866,509 B2
Humanized antibodies against CEACAM1
Tehila Ben-Moshe, Koranit (IL); Yair Sapir, Manof (IL); Ilana Mandel, Carmiel (IL); Gal Markel, Ramat Gan (IL); Jacob Schachter, Givataim (IL); Rona Ortenberg, Yokne'am Illit (IL); Francis Joseph Carr, Aberdeenshire (GB); Robert George E. Holgate, Royston (GB); and Timothy David Jones, Babraham (GB)
Assigned to FAMEWAVE LTD., Rehovot (IL)
Filed by Famewave Ltd., Rehovot (IL)
Filed on May 18, 2020, as Appl. No. 16/876,726.
Application 16/700,490 is a division of application No. 15/306,664, granted, now 10,550,196, issued on Feb. 4, 2020, previously published as PCT/IL2015/050433, filed on Apr. 27, 2015.
Application 16/876,726 is a continuation of application No. 16/700,490, filed on Dec. 2, 2019, granted, now 11,427,647.
Claims priority of provisional application 62/099,155, filed on Jan. 1, 2015.
Claims priority of provisional application 61/984,786, filed on Apr. 27, 2014.
Prior Publication US 2020/0277398 A1, Sep. 3, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/30 (2006.01); G01N 33/574 (2006.01); C12N 15/62 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61K 35/17 (2015.01); A61K 45/06 (2006.01)
CPC C07K 16/3007 (2013.01) [A61K 39/39558 (2013.01); C12N 15/62 (2013.01); G01N 33/57492 (2013.01); A61K 35/17 (2013.01); A61K 45/06 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70503 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A pharmaceutical composition comprising a humanized monoclonal antibody (mAb) or a fragment thereof, which specifically recognizes human Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), wherein the mAb or fragment thereof comprises:
(i) a heavy-chain variable region amino-acid sequence comprising the three CDR sequences set forth in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 and the four framework sequences set forth in: (a) SEQ ID NO:7 or SEQ ID NO:15; (b) SEQ ID NO:16 or SEQ ID NO:17; (c) SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21 or SEQ ID NO:22; and (d) SEQ ID NO:10 or SEQ ID NO:23;
and
(ii) a light-chain variable region amino-acid sequence comprising the three CDR sequences set forth in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, and the four framework sequences set forth in: (a) SEQ ID NO:11; (b) SEQ ID NO:24; (c) SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:27; and (d) SEQ ID NO:14;
and a pharmaceutically acceptable carrier, diluent or excipient.